Cannabidiol (CBD) Oil Does Not Display an Entourage Effect in Reducing Cancer Cell Viability in vitro.
CBD oil
Cannabidiol
Colorectal cancer
Entourage effect
Glioblastoma
Melanoma
Journal
Medical cannabis and cannabinoids
ISSN: 2504-3889
Titre abrégé: Med Cannabis Cannabinoids
Pays: Switzerland
ID NLM: 101765665
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
17
04
2020
accepted:
17
07
2020
entrez:
22
10
2021
pubmed:
23
10
2021
medline:
23
10
2021
Statut:
epublish
Résumé
Several studies have found that cannabinoids, particularly delta-9-tetrahydrocannabinol and cannabidiol (CBD), have the ability to reduce cancer cell viability. An ongoing debate regarding the use of medical Cannabis revolves around the effectiveness of pure compounds versus intact plant material for treatment. Proponents for the use of intact plant material or botanical extracts argue that there is a synergistic effect between the different cannabinoids, terpenoids, and flavonoids; this is commonly referred to as the "entourage effect." Our study was designed to test the validity of the proposed entourage effect in a narrow application using a cancer cell viability model. Six cancer cell lines, from 3 different types of human cancer were treated with 10 μM pure CBD or 10 μM CBD from hemp ( CBD (10 μM) was able to reduce cell viability in 3 of the 6 cell lines tested, and this was found to be cell line specific and not specific to select cancers. None of the CBD oils tested were able to reduce viability to a greater extent than that of pure CBD. Additionally, dose-response curves found lower IC We found that pure CBD was as potent or more potent at reducing cancer cell viability as the most potent oil tested, suggesting that there is no "entourage" effect under these specific in vitro conditions.
Identifiants
pubmed: 34676344
doi: 10.1159/000510256
pii: mca-0003-0095
pmc: PMC8489314
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95-102Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
K.E.V. and the Penn State College of Medicine are the recipients of research support from PA Options for Wellness (a state-approved medical marijuana clinical registrant). The funding source had no involvement in study design, data collection, analysis, and interpretation; writing of the report; or the decision to submit the article for publication. K.G. and R.G. Jr. are employees of Keystone State Testing, LLC (a Pennsylvania-approved medical marijuana testing laboratory). There are no other conflicts of interest or competing financial interests to disclose.
Références
J Crohns Colitis. 2019 Mar 30;13(4):525-535
pubmed: 30418525
Int J Cancer. 2007 Nov 15;121(10):2172-80
pubmed: 17583570
Bioorg Med Chem. 2015 Apr 1;23(7):1377-85
pubmed: 25703248
J Physiol Biochem. 2018 May;74(2):261-272
pubmed: 29441458
Acta Oncol. 2008;47(6):1062-70
pubmed: 17934890
J Pharmacol Exp Ther. 2006 Sep;318(3):1375-87
pubmed: 16728591
Drugs. 2013 Mar;73(3):249-62
pubmed: 23404093
Nutrients. 2020 Jan 30;12(2):
pubmed: 32019055
Mol Cancer Ther. 2014 Dec;13(12):2955-67
pubmed: 25398831
Mol Cancer Ther. 2010 Jan;9(1):180-9
pubmed: 20053780
Cancer Res. 2004 Mar 15;64(6):1943-50
pubmed: 15026328
PLoS One. 2013 Oct 21;8(10):e76918
pubmed: 24204703
Trends Pharmacol Sci. 2016 Jul;37(7):594-605
pubmed: 27179600
Front Plant Sci. 2019 Jan 09;9:1969
pubmed: 30687364
Cancer Lett. 2019 Apr 10;447:12-23
pubmed: 30660647
Eur J Pharmacol. 1998 Jul 17;353(1):23-31
pubmed: 9721036
Cannabis Cannabinoid Res. 2018 Dec 21;3(1):272-281
pubmed: 30671539
Carcinogenesis. 2014 Dec;35(12):2787-97
pubmed: 25269802
Cancer Res. 2006 Jul 1;66(13):6615-21
pubmed: 16818634
Br J Pharmacol. 2011 Aug;163(7):1344-64
pubmed: 21749363
Pain. 2017 Dec;158(12):2442-2451
pubmed: 28885454
Nat Rev Cancer. 2014 Nov;14(11):754-62
pubmed: 25291291
JAMA. 2017 Nov 7;318(17):1708-1709
pubmed: 29114823
Food Chem. 2018 Apr 15;245:943-950
pubmed: 29287463
Int Rev Psychiatry. 2018 Jun;30(3):277-284
pubmed: 30179534
Apoptosis. 2014 Jun;19(6):1029-42
pubmed: 24696378
J Clin Invest. 2009 May;119(5):1359-72
pubmed: 19425170
Molecules. 2018 May 20;23(5):
pubmed: 29783790
J Immunol. 2005 Mar 15;174(6):3281-9
pubmed: 15749859
Biochem Pharmacol. 2018 Nov;157:285-293
pubmed: 29940172
Eur J Pain. 2016 Jul;20(6):936-48
pubmed: 26517407